Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent, No Country
Key Data:
Drug (brand / generic)
Galvus (vildagliptin)
Company / licensee
Novartis
Therapy class
DPP-IV inhibitor
Product description
Inhibits action of DPP-IV, so delaying degradation of GLP-1
Current indication
Type 2 diabetes
Market sector
Diabetes
Development status
Approved Europe; pre-registration US
